Stable isotope labelling by amino acids in cell culture (SILAC) is an established technique used in quantitative mass spectrometry (MS)-based proteomics. SILAC is also used to generate stable isotope labelled (SIL) antibodies for internal standards (IS) used in LC-MS/MS bioassays to improve quantitative robustness.Total antibody (TAb) is measured to evaluate pharmacokinetics (PK) of antibody drug conjugate (ADC) candidates measured by either ligand binding (LBA) or LC-MS/MS. Herein, we describe an application of SILAC, where multiple SIL combinations of an antibody are used for cassette dosing and PK evaluation.Our preclinical studies demonstrate SILAC-labelled ADC therapeutics did not alter antibody PK. Furthermore, with cassette dosing SIL antibodies exhibited comparable exposure to discretely administered unlabelled test articles in rats.In addition, SIL antibodies were conjugated to cytotoxic payloads to create SIL ADCs and cassette dosed in a cynomolgus monkey PK study and SIL ADCs yielded comparable PK results to discrete dosed unlabelled ADCs.In conclusion, SIL antibodies used with a cassette dosing strategy increases PK screening throughput of ADC candidates in preclinical species. Additionally, cassette dosing strategy further facilitates the responsible use of laboratory animals to achieve the three-Rs (Replacement, Reduction, and Refinement).

Wireless networks are viewed as the best-used network and specifically Portable Specially Appointed Organizations (MANETs) have tracked down numerous applications for its information transmission progressively. The plan issues in this organization are to confine the utilization of energy while communicating data and give security to the hubs. Soa protocol needs to be energy efficient to avoid network failures. Thereby this paper brings an effective energy efficient to optimize LEAR and make it energy efficient. The energy-mindfulness element is added to the LEAR guiding convention in this work using the Binary Particle Swarm Optimization method (BPSO). The recommended method selects programmes taking into account course length in addition to the programme level of energy when predicting the future. To get good results, the steered challenge is first designed using LEAR. The next step is to choose a route that enhances the weighting capability of the study hours and programming power used.This MANET has been secured using the cryptographic method known as AES.According to experimental findings, the proposed hybrid version outperformed other cutting-edge models.

Background: Oxaliplatin (OX)-containing regimens are frequently utilized to treat gastrointestinal (GI) cancers. OX is eliminated predominately via urinary excretion (GFR and active tubular secretion). The contribution of active transport via OCT2 and MATE1/2-K to OX clearance is not fully understood. Tyrosine kinase inhibitors (TKIs) are frequently found to interact with OCT2/MATE transporters; however, a gap in knowledge remains between their clinical potential to impact OX pharmacokinetics (PK) and in turn, impact renal function. Tucatinib (TUC) is a highly selective human epidermal growth factor receptor 2 (HER2)-directed TKI approved in multiple regions in combination with trastuzumab and capecitabine for adult patients with metastatic HER2+ breast cancer and is currently being investigated in other HER2+ tumors. TUC inhibits OCT2/MATE-mediated transport of metformin and creatinine in vitro and in vivo. In this study, we investigated the impact of TUC on OX plasma PK, OX renal clearance (Clr), and renal function. Methods: In vitro inhibition of OCT2/MATE-mediated transport of OX by TUC was assessed in OCT2, MATE1, or MATE2-K-expressing MDCK-II cells. SGNTUC-024 (NCT04430738) is a Ph1b/2 clinical study in patients with HER2+ GI cancers evaluating the impact of TUC on the safety and PK of OX. Patients received TUC 150 mg (Cohort 1A) or 300 mg (Cohort 1B) BID starting on C1D8 of a 2-week cycle in combination with modified FOLFOX6/7. Intensive PK was collected in plasma and urine for OX alone (C1D1) or with steady-state TUC (C2D1). Total plasma platinum (Pt, analyzed as a surrogate for OX and catabolites), plasma Pt ultrafiltrate (PUF, unbound), and urine Pt were quantitatively analyzed via ICP-MS. Serum Cystatin C (CysC) was measured as a pharmacodynamic (PD) renal function marker in Cohorts 1A and 1B. Results: TUC inhibited in vitro OX transport by MATE1 (IC50 = 0.0639 µM), MATE2-K (IC50 = 0.0382 µM), and OCT2 (IC50 = 0.491 µM). In 11 patients, total Pt and PUF AUC0-8h geometric mean ratio (GMR) and 90% confidence intervals (CI) between patients who received OX alone compared to in combination were 1.1 (0.98, 1.3) and 1.0 (0.78, 1.4) in Cohort 1A (n=4) and 1.1 (0.96, 1.2) and 1.0 (0.98, 1.1) in Cohort 1B (n=7), respectively. OX GM (%CV) renal clearance (Clr,0-8h in mL/min) and fraction excreted 24h post-dose (fe,0-24h) were similar with and without TUC in both Cohort 1A (C1D1 Clr0-8h = 277 (33), fe,0-24h = 22% (17); C2D1 Clr0-8h = 249 (78), fe,0-24h = 21% (15)) and Cohort 1B (C1D1 Clr0-8h = 189 (37), fe,0-24h = 17.7% (16); C2D1 Clr0-8h = 177 (40), fe,0-24h = 16.6% (35)). Reversible slight increases in CysC (normalized to baseline) on day 3 of each cycle, irrespective of tucatinib, were observed. Conclusions: This investigation of in vitro and in vivo determinants of OX PK demonstrates that TUC does not alter the renal clearance of oxaliplatin nor renal function when OX is administered in combination with TUC. Citation Format: Ariel R. Topletz-Erickson, Anthony Lee, Vineet Kumar, Michelle Ubowski, JoAl G. Mayor, Layth I. Abdulrasool, Clark M. Henderson, Joseph A. Ware, Christopher J. Endres. Tucatinib does not alter oxaliplatin PK or associated renal function: An OCT2 and MATE transport inhibition study. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5060.

Abstract Integrin beta-6, a component of the heterodimeric adhesion receptor alpha-v/beta-6, is overexpressed in numerous solid tumors. Its expression has been shown by multiple investigators to be a negative prognostic indicator in diverse cancers including colorectal, non–small cell lung, gastric, and cervical. We developed SGN-B6A as an antibody–drug conjugate (ADC) directed to integrin beta-6 to deliver the clinically validated payload monomethyl auristatin E (MMAE) to cancer cells. The antibody component of SGN-B6A is specific for integrin beta-6 and does not bind other alpha-v family members. In preclinical studies, this ADC has demonstrated activity in vivo in models derived from non–small cell lung, pancreatic, pharyngeal, and bladder carcinomas spanning a range of antigen expression levels. In nonclinical toxicology studies in cynomolgus monkeys, doses of up to 5 mg/kg weekly for four doses or 6 mg/kg every 3 weeks for two doses were tolerated. Hematologic toxicities typical of MMAE ADCs were dose limiting, and no significant target-mediated toxicity was observed. A phase I first-in-human study is in progress to evaluate the safety and antitumor activity of SGN-B6A in a variety of solid tumors known to express integrin beta-6 (NCT04389632).

Abstract Purpose: This study evaluated the central nervous system (CNS) pharmacokinetics and target engagement of lapatinib, neratinib, and tucatinib in patients with cancer, using a physiologically based pharmacokinetic (PBPK) modeling approach. Experimental Design: Drug-specific parameters for in vitro metabolism, binding to plasma proteins and brain tissues, transcellular passive permeability, and interactions with efflux transporters were determined. Whole-body PBPK models integrated with a 4-compartment permeability-limited brain model was developed and verified for predicting plasma and CNS pharmacokinetics. Target engagement ratio (TER), defined as the ratio of the average steady-state unbound drug brain concentration (Css,ave,br) to in vitro IC50 for HER2 inhibition, was used as a predictor of intracranial efficacy. Results: PBPK models predicted that following 1 cycle of standard dosing, tucatinib and lapatinib achieved similar Css,ave,br (14.5 vs. 16.8 nmol/L), while neratinib Css,ave,br (0.68 nmol/L) was 20-fold lower. Tucatinib and neratinib were equally potent for HER2 inhibition (IC50, 6.9 vs. 5.6 nmol/L), while lapatinib was less potent (IC50, 109 nmol/L). The model-predicted population mean TER in the human normal brain was 2.1 for tucatinib, but < 0.20 for lapatinib and neratinib. Conclusions: The PBPK modeling suggests that tucatinib induces sufficient HER2 inhibition (TER > 2.0) in not only brain metastases with a disrupted blood–brain barrier (BBB), but also micrometastases where the BBB largely remains intact. These findings, in line with available clinical pharmacokinetics and efficacy data, support the therapeutic value of tucatinib for treatment of brain metastases and warrant further clinical investigation for the prevention of brain metastases in patients with HER2-positive breast cancer.

PURPOSE:Tucatinib, a small molecule for the treatment of metastatic HER2-positive breast cancer, was extensively metabolized in humans to multiple oxidative metabolites. To fully understand the elimination and biotransformation pathways of tucatinib, we investigated the in vitro and in vivo metabolism of tucatinib, and also conducted a Phase I trial using [14C]tucatinib.METHODS:To identify the responsible enzymes for tucatinib clearance, we investigated the in vitro metabolism of tucatinib including enzyme phenotyping, which facilitated the discovery of several metabolites in human and monkey plasma and excreta, in particular M1 (ONT-993, an aliphatic hydroxylated metabolite). Stereoselective formation of M1 was further investigated in vitro, in vivo, and in silico.RESULTS:In humans, approximately 86% of the total radiolabeled dose was recovered in feces and 4% in urine; in plasma, approximately 76% of radioactivity circulated as parent drug, with 19% attributed to multiple metabolites. The primary isoforms responsible for the elimination of tucatinib were CYP2C8 and CYP3A4/5. CYP2C8 was shown to possess sole catalytic activity for the formation of M1, whereas CYP3A4/5 and aldehyde oxidase catalyzed the formation of the remaining metabolites. Subsequent investigation revealed that M1 was formed in a stereoselective manner. Examination of the enantiomeric ratio of M1 stereoisomers observed in humans relative to cynomolgus monkeys revealed comparable results, suggesting that the enantiomers that comprise M1 were not considered to be unique or disproportionately high in human.CONCLUSION:CYP2C8 and CYP3A4/5 are the primary drug-metabolizing enzymes involved in the in vitro metabolism of tucatinib, which provided the basis to describe human disposition of tucatinib and formation of the observed metabolites.

The study was conducted to determine potential of urography using ionic and non-ionic contrast agents and urosonography and compare imaging quality and systemic effects of these agents. Eighteen dogs were equally divided into three groups, A, B and C. Animals of group A and B underwent intravenous urography with iohexol, and sodium and meglumine salt of diatrizoic acid, respectively. Urosonography was performed in animals of group C. Assessment of renal function, morphometric measurements and anatomical location of kidneys, ureters, urinary bladder and urethra was done. Systemic effects of contrast agents were evaluated clinically, haematologically and biochemically at different time intervals. Significantly (P<0.05) decreased haemoglobin, total erythrocyte count, packed cell volume, neutrophils, eosinophils and plasma calcium, and significantly (P<0.05) increased plasma creatinine, urea nitrogen and phosphorus were recorded in group B at 1 hr of contrast agent administration. Group A showed significant (P<0.05) decrease in eosinophils and increase in plasma creatinine at 1 hr interval post-injection of contrast agent. Left and right kidney volume was 33.27±1.58 and 37.085±2.12 cm3, respectively. Luminal diameter of ureter was 1.091±0.21 cm, pre-void bladder volume was 154.43±2.36 cm3, and the bladder wall thickness was 1.32±0.18 mm. Length and width of the bladder was 5.18±1.78 and 3.5±0.77 cm, respectively. Residual urine volume was 10.26±1.20 cc. It was concluded that iohexol produced better renal image and less systemic changes than that of meglumine. Ultrasonography is suitable for detecting echotexture and conducting morphometric measurements.

A 55-year old male patient presented to the Department of Oral and Maxillofacial Surgery with a swelling of the right submandibular region since four years [Table/Fig-1]. Swelling was painless asymptomatic and gradually increasing in size. On palpation swelling was firm with well-defined margins approximately (7x4 cm), swelling was mobile not fixed to overlying skin and no sign of inflammation. Patient was systemically normal. A tentative diagnosis was formed based on clinical examination which includes non-specific enlargement of right submadibular gland, lipoma, and lymphoma. [Table/Fig-1]: Clinical picture of lipoma in right submandibular region Contrast CT of right submandibular region showed a well circumscribed bilobed mass with mild extension into the parapharynegal space [Table/Fig-2] which was suggestive of benign lipomatous condition. A decision was made to surgically explore the lesion. [Table/Fig-2]: Contrast CT scan of the right submandibular region revealing the bilobed Tumour mass with mild extension into the parapharyngeal space After obtaining pre anaesthetic clearance, patient was admitted for excision of mass under GA [Table/Fig-3]. A submandibular incision was given to create access to soft tissue mass blunt dissection was done preserving marginal mandibular branch of facial nerve and a yellowish bilobed soft encapsulated mass was excised [Table/Fig-4,​,5].5]. Postoperative recovery was uneventful. Histological examination under 5 x magnifications showed sheets of mature adipocytes and lobules of adipose tissue separated from the surface epithelium by fibrous connective tissue stroma. The adipocytes were loosely arranged in large areas which showed presence of empty cytoplasm and small nuclei. Tumour cells were arranged in lobules. These lobules were separated from each other by fibrovascular connective tissue septae [Table/Fig-6]. [Table/Fig-3]: Outline of submandibular incision along with marking of inferior border of the mandible in order to save the marginal mandibular nerve during dissection [Table/Fig-4]: Intraoperative view of bilobed lesion separated from surrounding structures [Table/Fig-5]: Completely excised lesion along with parapharyngeal extension [Table/Fig-6]: Depicting the mature adipocytes and fat lobules separated by fibrous septae The presence of lipoma in the submandibuar region is extremely rare and it accounts for only 1-2% of all lipomas of the body. Angiolipomas and infiltrating lipomas are rarely found in the oral cavity [1] . There have been reports of deep intra muscular lipoma in the submandibular region by Adachi et al., [2] . Pusiol e t al., reported an oncocyticsialo lipoma of submandibular gland [3] . Diagnostic imaging techniques such as ultrasonograpghy, MRI and CT help to differentiate lipomas from other soft tissue lesion. And helps to identify the nature and exact location of lesion. However, the soft tissue characterization with ultrasonography is less specific than CT or MRI. When the mass is difficult to identify on ultrasonogram, CT or MRI is necessary. On CT scan it shows a high density from 83 to 143 Hounsfield units with well or poorly defined margins depending on the capsule [4].

A two month old pup was presented with congenital preputial defect. Preputial stenosis was repaired by surgical intervention under general anesthesia. Postoperatively, the pup recovered uneventfully without any complications. Sutures were removed on 8th post-operative days. No adhesion of penis was noticed and urination was completely normal.

Overuse injuries in young adults present a unique challenge to the treating clinician. In this study, we studied the association of male-alignment as a risk factor for overuse injuries of the lower extremity in young adults. This prospective cohort study examined all the adult patients presented with various lower extremity overuses injuries. Only those engaged in unorganised sports activity were studied. After making a clinical impression, all patients were subjected to relevant X-rays to diagnose the malalignment, if present or not. A total of 252 cases with overuse injuries was included, in which seventythree per cent were male patients. The sprain ankle was the commonest overuse injury to both genders. In our study, the mal-alignment was seen in 64.3% of the total overuse cases, of which the commonest malalignment in both genders was internal tibial torsion. In conclusions overuse injuries in young adults are frequently associated with mal-alignments. Better understanding of these mal-alignments are better for the management of these injuries.

Structural elucidation is an integral part of drug discovery and development. In recent years, due to acceleration of the drug discovery and development process, there is a significant need for highly efficient methodologies for structural elucidation. In this work, we devised and standardized a simple and economical online hydrogen deuterium exchange methodology, which can be used for structure elucidation purposes.Deuterium oxide (D2O) was infused as a postcolumn addition using the syringe pump at the time of elution of the analyte. The obtained hydrogen/deuterium (H/D) exchange spectrum of the unknown analyte was compared with the nonexchanged spectrum, and the extent of deuterium incorporation was delineated by using an algorithm to deconvolute partial H/D exchange, which confirmed the number of labile hydrogen(s) in the analyte. The procedure was standardized by optimizing flow rates of LC output, D2O infusion, sheath gas, and auxiliary gas using the model compound sulfasalazine. The robustness of the methodology was demonstrated by performing sensitivity analysis of various parameters such as concentrations of analyte, effect of matrices, concentrations of aqueous mobile phase, and types of LC modifiers. The optimized technique was also applied to chemically diverse analytes and tested on various mass spectrometers. Moreover, utility of the technique was demonstrated in the areas of impurity profiling and metabolite identification, taking pravastatin-lactone and N-oxide desloratidine, as examples.